Who's afraid of incompatible plasma? A balanced approach to the safe transfusion of blood products containing ABO-incompatible plasma

Transfusion

Volumn 58, Issue 2, 2018, Pages 532-538

  Yazer, Mark H ^a   Seheult, Jansen ^a   Kleinman, Steven ^b   Sloan, Steven R ^c   Spinella, Philip C ^d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; ISOHEMAGGLUTININ; UNCLASSIFIED DRUG;

ANTIBODY TITER; APHERESIS; BLOOD GROUP A; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD GROUP O; BLOOD TRANSFUSION; CLINICAL PRACTICE; HEMOLYSIS; HUMAN; NOTE; RISK ASSESSMENT; SAFETY; BLOOD COMPONENT THERAPY; BLOOD GROUP ABO SYSTEM; BLOOD GROUP INCOMPATIBILITY; PLASMA;

ABO BLOOD-GROUP SYSTEM; BLOOD COMPONENT TRANSFUSION; BLOOD GROUP INCOMPATIBILITY; HUMANS; PLASMA;

EID: 85041412039     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.14415     Document Type: Note

References (44)

1. Grove-Rasmussen M. Selection of “safe” group O blood. Transfusion 1966;6:331-5.
2. Grove-Rasmussen M, Shaw RS, Marceau E. Hemolytic transfusion reaction in group-A patient receiving group-O blood containing immune anti-A antibodies in high titer. Am J Clin Pathol 1953;23:828-32.
3. Blumberg N, Refaai M, Heal J. ABO matching of platelet transfusions—“Start Making Sense”. “As we get older, and stop making sense…”—The Talking Heads (1984). Blood Transfus 2015;13:347-50.
4. Refaai MA, Carter J, Henrichs KF, et al. Alterations of platelet function and clot formation kinetics after in vitro exposure to anti-A and -B. Transfusion 2013;53:382-93.
5. Refaai MA, Fialkow LB, Heal JM, et al. An association of ABO non-identical platelet and cryoprecipitate transfusions with altered red cell transfusion needs in surgical patients. Vox Sang 2011;101:55-60.
6. Cooling LL, Downs TA, Butch SH, et al. Anti-A and anti-B titers in pooled group O platelets are comparable to apheresis platelets. Transfusion 2008;48:2106-13.
7. Dunbar NM, Yazer MH. Safety of the use of group A plasma in trauma: the STAT study. Transfusion 2017;57:1879-84.
8. Bahr MP, Yazer MH, Triulzi DJ, et al. Whole blood for the acutely haemorrhaging civilian trauma patient: a novel idea or rediscovery? Transfus Med 2016;26:406-14.
9. Cooling L. ABO and platelet transfusion therapy. Immunohematology 2007;23:20-33.
10. McManigal S, Sims KL. Intravascular hemolysis secondary to ABO incompatible platelet products. An underrecognized transfusion reaction. Am J Clin Pathol 1999;111:202-6.
11. Duguid JK, Minards J, Bolton-Maggs PH. Lesson of the week: incompatible plasma transfusions and haemolysis in children. BMJ 1999;318:176-7.
12. Zoes C, Dube VE, Miller HJ, et al. Anti-A1 in the plasma of platelet concentrates causing a hemolytic reaction. Transfusion 1977;17:29-32.
13. Michelis FV, Branch DR, Scovell I, et al. Acute hemolysis after intravenous immunoglobulin amid host factors of ABO-mismatched bone marrow transplantation, inflammation, and activated mononuclear phagocytes. Transfusion 2014;54:681-90.
14. Yazdanbakhsh K. Controlling the complement system for prevention of red cell destruction. Curr Opin Hematol 2005;12:117-22.
15. Mair B, Benson K. Evaluation of changes in hemoglobin levels associated with ABO-incompatible plasma in apheresis platelets. Transfusion 1998;38:51-5.
16. Cid J, Harm SK, Yazer MH. Platelet transfusion—the art and science of compromise. Transfus Med Hemother 2013;40:160-71.
17. Strandenes G, Berséus O, Cap AP, et al. Low titer group O whole blood in emergency situations. Shock 2014;41Suppl 1: 70-5.
18. Spinella PC, Pidcoke HF, Strandenes G, et al. Whole blood for hemostatic resuscitation of major bleeding. Transfusion 2016;56 Suppl 2:S190-202.
19. Karafin MS, Blagg L, Tobian AA, et al. ABO antibody titers are not predictive of hemolytic reactions due to plasma-incompatible platelet transfusions. Transfusion 2012;52:2087-93.
20. McLeod BC, Sassetti RJ, Weens JH, et al. Haemolytic transfusion reaction due to ABO incompatible plasma in a platelet concentrate. Scand J Haematol 1982;28:193-6.
21. Pierce RN, Reich LM, Mayer K. Hemolysis following platelet transfusions from ABO-incompatible donors. Transfusion 1985;25:60-2.
22. Ferguson DJ. Acute intravascular hemolysis after a platelet transfusion. CMAJ 1988;138:523-4.
23. Josephson CD, Castillejo MI, Grima K, et al. ABO-mismatched platelet transfusions: strategies to mitigate patient exposure to naturally occurring hemolytic antibodies. Transfus Apher Sci 2010;42:83-8.
24. Berséus O, Boman K, Nessen SC, et al. Risks of hemolysis due to anti-A and anti-B caused by the transfusion of blood or blood components containing ABO-incompatible plasma. Transfusion 2013;53:114S-23S.
25. Angiolillo A, Luban NL. Hemolysis following an out-of-group platelet transfusion in an 8-month-old with Langerhans cell histiocytosis. J Pediatr Hematol Oncol 2004;26:267-9.
26. Valbonesi M, De Luigi MC, Lercari G, et al. Acute intravascular hemolysis in two patients transfused with dry-platelet units obtained from the same ABO incompatible donor. Int J Artif Organs 2000;23:642-6.
27. Belin TR, Yazer MH, Meledeo MA, et al. An evaluation of methods for producing low-titer group O whole blood to support military trauma resuscitation. J Trauma Acute Care Surg 2017;82:S79-86.
28. AuBuchon JP, de Wildt-Eggen J, Dumont LJ, et al. Reducing the variation in performance of antibody titrations. Arch Pathol Lab Med 2008;132:1194-201.
29. Josephson CD, Mullis NC, Van Demark C, et al. Significant numbers of apheresis-derived group O platelet units have “high-titer” anti-A/A,B: implications for transfusion policy. Transfusion 2004;44:805-8.
30. Sadani DT, Urbaniak SJ, Bruce M, et al. Repeat ABO-incompatible platelet transfusions leading to haemolytic transfusion reaction. Transfus Med 2006;16:375-9.
31. Daniel-Johnson J, Leitman S, Klein H, et al. Probiotic-associated high-titer anti-B in a group A platelet donor as a cause of severe hemolytic transfusion reactions. Transfusion 2009;49:1845.
32. Sprogoe U, Yazer MH, Rasmussen MH, et al. Minimal variation in anti-A and -B titers among healthy volunteers over time: implications for the use of out-of-group blood components. J Trauma Acute Care Surg 2017;82:S87-90.
33. Dunbar NM, Yazer MH; Biomedical Excellence for Safer Transfusion Collaborative. A possible new paradigm? A survey-based assessment of the use of thawed group A plasma for trauma resuscitation in the United States. Transfusion 2016;56:125-9.
34. Stubbs JR, Zielinski MD, Jenkins D. The state of the science of whole blood: lessons learned at Mayo Clinic. Transfusion 2016;56 Suppl 2:S173-81.
35. Seheult JN, Triulzi DJ, Alarcon LH, et al. Measurement of haemolysis markers following transfusion of uncrossmatched, low-titre, group O+ whole blood in civilian trauma patients: initial experience at a level 1 trauma centre. Transfus Med 2017;27:30-5.
36. Filbey D, Hanson U, Wesström G. The prevalence of red cell antibodies in pregnancy correlated to the outcome of the newborn: a 12 year study in central Sweden. Acta Obstet Gynecol Scand 1995;74:687-92.
37. Branch DR, Gallagher MT, Mison AP, et al. In vitro determination of red cell alloantibody significance using an assay of monocyte-macrophage interaction with sensitized erythrocytes. Br J Haematol 1984;56:19-29.
38. Cunnion KM, Hair PS, Krishna NK, et al. Discriminating the hemolytic risk of blood type A plasmas using the complement hemolysis using human erythrocytes (CHUHE) assay. Transfusion 2017;57:517-24.
39. Cunnion KM, Hair PS, Krishna NK, et al. Discriminating complement-mediated acute transfusion reaction for type O+ red blood cells transfused into a B+ recipient with the complement hemolysis using human erythrocytes (CHUHE) assay. Transfusion 2016;56:1845-8.
40. Win N. High titre anti-A/B testing of donors within NHS Blood and Transplant (NHSBT). INF 178/2. London: NBS; 2012.
41. Standards for blood banks and transfusion services. 30th ed. Bethesda (MD): AABB; 2016.
42. Quillen K, Sheldon SL, Daniel-Johnson JA, et al. A practical strategy to reduce the risk of passive hemolysis by screening plateletpheresis donors for high-titer ABO antibodies. Transfusion 2011;51:92-6.
43. MacLennan S. High titre anti-A/B testing of donors within the National Blood Service (NBS). INF/MED/MA/004/02. London: NBS; 2006.
44. Transfusion of apheresis platelets and ABO groups. Vox Sang 2005;88:207-21.